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Pharmacologic interventions designed to preserve ischemic myocardium 
have been the subject of extensive basic and clinical investigation over the 
past 10 ~ e a r s . l - ~  Whereas most of these studies have been concerned with the 
concept of feasibility of reduction of infarct size by a variety of means, none 
has looked systematically at the long-term sequelae of such interventions, par- 
ticularly with regard to late-phase arrhythmias and sudden death. The purpose 
of this paper is to briefly review the rationale behind infarct size reduction and 
then to present some experimental data which question the advisability of 
widespread use of pharmacologic reduction of infarct size as an isolated clinical 
strategy. 
Without attempting an exhaustive review of literature, I have chosen a 
few clinical studies that I believe are either pro or con the concept of infarct size 
reduction. Although these studies are not necessarily intended as such, they 
form the background for our investigations. 
The rationale for preserving ischemic myocardium stems from both patho- 
logic 4, studies that show a direct relationship between infarct 
size and subsequent clinical course with respect to the development of congestive 
heart failure and cardiogenic shock and also with respect to prognosis. Work 
by Roberts et al.' and Cox et aL8 has shown a direct relationship between infarct 
size as determined by creatine phosphokinase (CPK) measurements and the 
frequency of ventricular arrhythmias in the first 20 hours after acute myocardial 
infarction. These studies suggest that the frequency of early ventricular 
arrhythmias after acute myocardial infarction reflects the extent of myocardial 
injury. 
Schulze et aL9 have investigated the relationship of complex ventricular 
arrhythmias (Lown Class 111-V) 10 to 21 days post infarction to left ven- 
tricular dysfunction using Holter monitor recordings and gated blood pool scans. 
Patients with these late-phase complex ventricular arrhythmias were found to 
have significantly lower ejection fractions and presumably larger infarcts than 
did patients without complex ventricular arrhythmias. The overall survival in 
the group with complex arrhythmias was less than 50%, despite standard anti- 
arrhythmic therapy. 
On the basis of these studies, one could postulate that reduction of infarct 
size should reduce the incidence of postinfarction arrhythmias, both early and 
late, and subsequently reduce the tendency to the development of ventricular 
fibrillation and sudden death. 
These studies are just a few of the many investigations that have provided 
the basis for attempts to limit infarct size. 
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Recent studies suggest, however, that in addition to infarct size, areas of 
jeopardized myocardium play an important role in the etiology of post- 
infarction arrhythmias. Schaeffer and Cobb lo have reported the Seattle experi- 
ence with survivors of out-of-hospital ventricular fibrillation. They found that 
recurrent ventricular fibrillation or sudden death developed primarily in those 
patients whose initial episode was not associated with myocardial infarction. 
Despite lack of evidence of myocardial necrosis, this group of patients remains at 
a high risk for the development of malignant ventricular arrhythmias. This 
suggests that these patients have an area of myocardium at risk for the develop- 
ment of ischemia-related changes in myocardial activation and repolarization 
with resultant malignant arrhythmias. In contrast, those patients who have 
evidence of a completed infarction after resuscitation do not have an area of 
jeopardized myocardium at risk for subsequent ischemia and malignant 
arrhythmias. 
Recent angiographic studies by Taylor et ~ 1 . ~ ~  have identified groups of 
patients at different degrees of risk for sudden death after infarction. Those 
patients at low risk for the development of sudden death were those with an 
occluded vessel leading to an akinetic myocardial segment with all other areas 
of ventricle showing normal wall motion. The patients at highest risk were 
those with an occluded or partially narrowed vessel supplying the hypokinetic 
myocardial segment. This suggests that patients with a completed infarct who 
do not have an area of jeopardized myocardium fare better from the standpoint 
of sudden death than do those patients with a segment of myocardium at risk 
for subsequent ischemia. 
Finally, population studies I3 have shown that patients surviving an 
episode of subendocardial infarction have a risk of recurrent infarction and 
sudden death equal to or greater than that of patients with transmural infarction. 
This again suggests that despite a smaller area of myocardial necrosis, patients 
with subendocardial infarction have an area of jeopardized myocardium which 
may lead to recurrent infarction and sudden death. 
Thus, on the basis of these studies, one can postulate that reduction of 
infarct size by pharmacologic intervention, by salvaging viable yet jeopardized 
myocardium, may increase the risk for the development of malignant ar- 
rhythmias and sudden death. 
While many pharmacdogic agents have been shown to limit the extent 
of myocardial necrosis resulting from coronary occlusion, propranolol has been 
consistently effective in reducing infarct size in a variety of animal models l4 
and in two clinical studies. In one clinical study, Norris et ul.15 gave intravenous 
propranolol, 0.1 mgl kg, to patients with acute myocardial infarction within 4 
hours of the onset of symptoms and this was followed by oral propranolol for 
several days. These investigators were able to show a decrease in the number 
of completed (Q wave) infarcts and lower peak CPK values in the propranolol- 
treated patients than in control patients. So from this study it appears that the 
concept of infarct size reduction in the clinical setting is feasible. 
With this background in mind, we undertook a series of experiments 
designed to test the hypothesis that pharmacologic reduction of infarct size 
may be detrimental to electrophysiologic stability after acue myocardial infarc- 
tion. In choosing an experimental model, we wanted to be able to achieve 
several goals. First, we wanted to achieve maximal infarct size reduction. 
Second, most of the earlier experiments that studied the relationship between 
ventricular arrhythmias and infarct size reduction used anesthetized animals. 
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Since anesthesia may have a profound effect on arrhythmia development, we 
wanted to be able to monitor for arrhythmias in the conscious, unsedated animal. 
Third, in addition to looking at spontaneous ventricular arrhythmias, we wanted 
to have another measure of electrical stability in the conscious animal. In order 
to do this, we wanted a model in which we could attempt to induce ventricular 
tachycardia by means of programmed electrical stimulation in the conscious dog 
after myocardial infarction. 
In order to achieve maximal infarct size reduction, we performed a 90- 
minute proximal occlusion of the left anterior descending (LAD) artery, 
followed by reperfusion through a critical stenosis in anesthetized male mongrel 
dogs weighing between 10 and 20 kg. Group I animals received pretreatment 
with intravenous propranolol, 1 mg/ kg, 30 minutes before LAD occlusion. 
Group I1 animals received an equal volume of saline solution 30 minutes 
before occlusion and served as controls, and Group I11 animals were sham- 
operated controls who underwent thoracotomy and electrode placement only. 
All animals were monitored continuously intraoperatively for determination of 
electrocardiographic rhythm and blood pressure. The number and complexity 
of ventricular arrhythmias during the 90-minute period of LAD occlusion and 
for 30 minutes after LAD reperfusion were quantitated. After 30 minutes of 
reperfusion, bipolar electrodes were attached to the left atrium and right 
ventricular outflow tract to be used for subsequent recording and programmed 
stimulation studies. The animals were then allowed to recover and subse- 
quently were monitored daily while standing in a sling, unsedated, for a period 
of 1 hour until the disappearance of spontaneous ventricular arrhythmias. 
Significant ventricular arrhythmias were arbitrarily defined as being equal to or 
greater than 10 premature ventricular depolarizations per minute. This enabled 
us to assess the time course of spontaneous ventricular ectopy in the conscious 
animal after myocardial infarction. On the first day in which no significant 
ventricular ectopy was recorded, the animals underwent programmed electrical 
stimulation studies using the indwelling electrodes. The stimulation protocol 
consisted of both atrial and ventricular pacing with the introduction of single 
and double ventricular extrastimuli as well as short bursts of rapid ventricular 
pacing to a maximal rate of 250 per minute. The animals were then sacrificed 
and infarct size determined by triphenyl tetrazolium staining and direct gravi- 
metric analysis and expressed as percent of left ventricular mass. 
Animals that were pretreated with propranolol developed an infarct that 
was on the average 20% of the left ventricular mass and this was significantly 
smaller (p  < 0.005) than the infarct size in the control animals, which aver- 
aged 30% of left ventricular mass. However, despite significant infarct size 
reduction, the time course of spontaneous ventricular arrhythmias after infarc- 
tion was prolonged in the propranolol-treated animals compared with the 
control group. Thus, by 72 hours after occlusion, half of the propranolol- 
treated animals still had significant ventricular ectopy, whereas none of the 
control animals continued to display significant% arrhythmias by this time. By 
96 hours after occlusion, both groups of animals were quiescent from the 
standpoint of spontaneous ventricular ectopy. Despite this difference between 
the two groups in the time course of spontaneous ventricular arrhythmias, there 
was no difference in the ability to induce ventricular tachycardia by means of 
programmed stimulation between the two groups. 
Of interest, none of the sham-operated control animals exhibited any 
spontaneous ventricular ectopy nor did they exhibit induced ventricular tachy- 
cardia, and none had any evidence of infarction by our staining techniques. 
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SUMMARY 
These experiments show that pretreatment with propranolol was able to  
achieve significant infarct size reduction in  this particular animal model of LAD 
occlusion followed by reperfusion through a critical stenosis. Despite infarct 
size reduction, the propranolol pretreatment prolonged the time course of 
spontaneous ventricular arrhythmias after acute myocardial infarction in the 
conscious dog. In  contrast to  this, propranolol pretreatment did not appear t o  
protect against inducible ventricular arrhythmias in the late postinfarction 
period in the conscious dog. 
While it is, of course, impossible t o  extrapolate the results of animal studies 
to the clinical situation, future clinical studies designed to limit infarct size by 
pharmacologic intervention should specifically address the question of electro- 
physiologic instability after myocardial infarction, both in  the early and late 
phases. T h e  possibility exists that pharmacologic limitation of infarct size may 
preserve viable but potentially jeopardized areas of myocardium, leaving the 
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DISCUSSION 
DR. BIGGER: I would like to discuss your remark concerning persons with 
nontransmural myocardial infarction who are now recognized as being at risk 
of early reinfarction or death. You attribute this risk to the possibility of the 
occurrence of arrhythmias, but it seems to me that the risk is just as likely to 
occur through ischemia or left ventricular dysfunction. 
DR. STEWART: I didn’t mean to imply a primary arrhythmic etiology, but 
I did mean to imply that without a transmural infarction, there is an area of 
myocardium presumably in jeopardy for ischemia-related reinfarction or 
ischemia-related arrhythmic changes. 
DR. BIGGER: Do all beta adrenergic blocking agents have the same effects 
as those you showed with propranolol? Or is it possible that they are not all 
the same? 
DR. STEWART: here is no way I can answer that since we did not investi- 
gate other beta blockers in our study. 
DR. SCHWARTZ: As to the higher incidence of arrhythmias at 72 hours: 
Is there any difference in heart rate between the two groups? A lower heart rate 
with propanalol might have favored the appearance of arrhythmias. Also I am 
concerned about your way of inducing infarction. Reperfusion is very nice, but 
I wonder whether you are not somehow changing the situation, which may be 
far different from what happens with complete stenosis. Before extrapolations 
are made from your studies, it would be good to repeat the study with a more 
traditional method of coronary arterial occlusion. 
DR. STEWART: Your points are well taken. In the clinical situation both 
effects are probably operative. Certainly, infarctions are due to complete 
occlusion, but recent angiographic studies of infarcts have shown reperfusion 
in patients within hours after acute infarction. 
DR. MASERI: I want to make two points. First, you were very careful 
to point out that you were describing the results in your model in terms of 
reducing infarct size. What happens in daily life with patients may be slightly 
different from what happens to an experimental animal whose artery is occluded 
and perhaps released. 
Second, it is very important, when looking at sudden death after myocardial 
infarction, to determine whether these sudden deaths are related to arrhythmias 
per se or to a new episode of ischemia, because if they are related to a new 
episode of ischemia, then we must strive to prevent such an occurrence. 
Conversely, if they are related to primarily electrical instability, then anti- 
arrhythmic drugs may have a place. The distinction between causes must be 
made. 
DR. STEWART: I agree with you completely. The main emphasis should 
be placed on preventing subsequent ischemia. 
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DR. LOZNER: Dr. Pitt’s earlier review made the point that survival after 
myocardial infarction really depends on how much damage has been done to 
the ventricle. The cumulative effects of multiple infarctions identify the 
patients who do not do well. Nobody has mentioned yet that we have an 
exciting clinical tool on the horizon for limiting infarct size by lysing coronary 
thrombi within hours of the infarction. Although those patients may be at 
early risk of arrhythmias, especially at the time of reperfusion, a patient whose 
infarct has been markedly limited by that technique is going to do better over the 
long term than will someone who just sits and hopes for one of the “good” 
kinds of infarction, which is a nice neat package with no ischemic area. 
DR. STEWART: I have two comments on that: First, the streptokinase 
studies may be more relevant to our reperfusion models. Second, patients who 
receive streptokinase will continue to have a high-grade stenosis in the vessel 
that was initially responsible for the infarction. If nothing is done about the 
residual high-grade stenosis, the person is again at a high risk of subsequent 
infarction. 
